-- Four oncology molecules in clinical development; on track to have six by 2015 year-end
-- Margetuximab Phase 3 study in metastatic breast cancer to initiate in 2015
-- MGD007 (gpA33 x CD3 DART) first patients dosed in colorectal cancer
-- MGD011 (CD19 x CD3 DART) introduced
"With four oncology programs now in the clinic, including DARTs against both hematological malignancies and solid tumors,
"This new direction for margetuximab is grounded in both emerging science and the data we have seen to date, as well as significant input from key opinion leaders and payers," commented
Update on Product Candidates
Margetuximab is an Fc-optimized monoclonal antibody that targets HER2. Recent highlights include:
- New Phase 3 Breast Cancer Study: The new Phase 3 pivotal study will evaluate margetuximab plus chemotherapy against the current standard of care in third-line metastatic breast cancer patients with HER2 expression at the 3+ level by immunohistochemistry (IHC) or 2+ level by IHC with gene amplification. The new Phase 3 study in breast cancer is anticipated to begin in the third quarter of 2015. MacroGenics projects that the time to regulatory filing for this indication should occur in a timeframe similar to that for the previously planned MAGENTA Phase 3 gastroesophageal cancer study.
- Gastroesophageal Cancer Opportunity: The Company plans to initiate Phase 1/2 combination studies in gastroesophageal cancer and will no longer be pursuing the MAGENTA study.
- Ongoing Phase 2a Clinical Study: Patient enrollment continues in the Company's exploratory Phase 2a study in metastatic breast cancer patients with HER2 expression at the 1+ or 2+ level by IHC without gene amplification. The dosing of this study is being changed from once weekly to once every three weeks.
MGA271 is an Fc-optimized monoclonal antibody that targets B7-H3, a member of the B7 family of molecules involved in immune regulation. The Company recently initiated recruitment of patients in multiple additional monotherapy expansion cohorts across various tumor types, including triple-negative breast cancer, head and neck cancer, renal cell cancer, melanoma (after failing a previous immune therapy), and a cohort consisting of non-small cell lung cancer and bladder cancer patients with the highest level of B7-H3 expression. MacroGenics also plans to initiate further studies of MGA271 in combination with other therapies in 2015.
MGD006 is a Dual-Affinity Re-Targeting (DART) molecule that recognizes both CD123 and CD3.
MGD007 is a DART molecule that recognizes both the glycoprotein A33 antigen, or gpA33, and CD3. Recent highlights include:
Dosing Phase 1 Clinical Study:
MacroGenicsrecently began dosing patients in a Phase 1 study of MGD007 for the treatment of colorectal cancer. MGD007 represents the second DART molecule to enter the clinic, and the Company's first DART molecule dosed in patients with solid tumors.
Milestone Payment by Servier: During the third quarter,
MacroGenicsreceived a $5 millionmilestone payment from Servier triggered by the FDAclearance of the Phase 1 study. Servier has the option to obtain an exclusive license to develop and commercialize this program in all territories outside of North America, Japan, Korea, and India. MacroGenicsretains development and commercialization rights to these territories.
Continued Progress on MGD010: MGD010 is a DART molecule that simultaneously targets CD32B and CD79B, which are two B-cell surface proteins. MGD010 is designed to inhibit B-cell activation by exploiting the inhibitory function of CD32B, a checkpoint molecule expressed by B cells. MGD010 is currently in pre-clinical development for the treatment of autoimmune disorders. MacroGenics expects to initiate a Phase 1a study in 2015. Upon completion of this study, Takeda will have the option to obtain an exclusive worldwide license for MGD010 by paying a license option fee, pursuant to a
May 2014collaboration agreement.
Introducing MGD011: MGD011, a humanized CD19 x CD3 DART, is one of the two oncology-based DART candidates that
MacroGenicsintends to take into clinical development in 2015. The MGD011 pre-clinical data and the molecule's extended pharmacokinetic properties support dosing at intervals of once per week or longer.
Expanded Takeda Relationship: During the third quarter,
MacroGenicsand Takeda jointly announced that they entered into a collaboration agreement to develop and commercialize up to four product candidates, which are in addition to MGD010. Each of these product candidates will be directed against jointly selected pairs of molecular targets and incorporate MacroGenics'DART platform. Assuming successful development and commercialization by Takeda, MacroGenicscould receive up to an additional approximately $400 millionin payments for each of the four potential product candidates.
Partnered Program Milestone: During the third quarter,
MacroGenicsachieved a milestone for a DART program partnered with Boehringer Ingelheim that triggered a $2 millionpayment due to MacroGenics.
Universal Shelf Registration Statement Filing:
MacroGenicsintends to file a shelf registration statement with the SECcovering the potential sale of up to $150 millionof securities. Although MacroGenics expects to have the flexibility under the shelf registration statement, if and when it is declared effective, to more quickly access the capital markets with either equity or debt securities offerings, MacroGenicshas no immediate plans to issue any such securities.
2014 Third Quarter Financial Results
Cash Position: Cash and cash equivalents as of
September 30, 2014were $179.2 million, compared to $116.5 millionas of December 31, 2013.
Revenue: Total revenues, consisting primarily of revenue from collaborative research, were
$18.4 millionfor the quarter ended September 30, 2014, compared to $20.2 millionfor the quarter ended September 30, 2013. Collaborative research revenue includes the recognition of deferred revenue from payments received in previous periods as well as payments received during the quarter.
R&D Expenses: Research and development expenses were
$18.6 millionfor the quarter ended September 30, 2014, compared to $11.1 millionfor the quarter ended September 30, 2013.
G&A Expenses: General and administrative expenses were
$3.7 millionfor the quarter ended September 30, 2014, compared to $2.0 millionfor the quarter ended September 30, 2013.
Net Loss: Net loss was
$3.9 millionfor the quarter ended September 30, 2014, compared to net income of $6.6 millionfor the quarter ended September 30, 2013.
Shares Outstanding: Shares outstanding as of
October 31, 2014were 27.8 million.
Conference Call Information
The recorded, listen-only webcast of the conference call can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at http://ir.macrogenics.com/events.cfm. A replay of the webcast will be available shortly after the conclusion of the call and archived on the Company's website for 30 days following the call.
|CONSOLIDATED BALANCE SHEET DATA|
|(Amounts in thousands)|
|Cash and cash equivalents||$ 179,191||$ 116,481|
|Total stockholders' equity||139,088||78,914|
|CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS|
|(Amounts in thousands, except share and per share data)|
Three Months Ended
Nine Months Ended
|Revenue from collaborative research||$ 18,283||$ 20,111||$ 41,886||$ 42,016|
|Costs and expenses:|
|Research and development||18,632||11,088||50,536||32,234|
|General and administrative||3,678||1,986||11,081||7,323|
|Total costs and expenses||22,310||13,074||61,617||39,557|
|Income (loss) from operations||(3,928)||7,158||(19,296)||3,571|
|Other income (expense)||-||(554)||1||(627)|
|Net comprehensive income (loss)||$ (3,928)||$ 6,604||$ (19,295)||$ 2,944|
|Basic net income (loss) per common share||
|Diluted net income (loss) per common share||
|Basic weighted average common shares outstanding||27,751,437||1,184,507||27,227,151||1,463,798|
|Diluted weighted average common shares outstanding||27,751,437||21,242,979||27,227,151||21,908,859|
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or jurisdiction in which the offer, solicitation or sale would be unlawful. This announcement is being issued pursuant to, and in accordance with, Rule 135 under the Securities Act of 1933, as amended.
Cautionary Note on Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects for the Company, including statements about the Company's strategy, future operations, clinical development of the Company's therapeutic candidates, milestone or opt-in payments from the Company's collaborators, the Company's future expectations and plans and prospects and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation and
enrollment of future clinical trials, expectations of expanding ongoing clinical trials, availability and timing of data from ongoing clinical trials, expectations for regulatory approvals, other matters that could affect the availability or commercial potential of the Company's product candidates and other risk factors described in the Company's filings with the
Jim Karrels, Vice President, CFO MacroGenics, Inc.1-301-251-5172, firstname.lastname@example.org Karen Sharma, Vice President MacDougall Biomedical Communications1-781-235-3060, email@example.com
News Provided by Acquire Media